Phase III for a bespoke mRNA cancer therapy repriced the sequencing vendors, not just Moderna

Moderna's December 2023 Phase IIb data in stage III/IV melanoma, reported with the same partner, moved its stock 10% ^[15]. The Phase III headline moved it 130.5% across three sessions ^[14], about thirteen times as much ^[1], and it did so on the strength of a phase label rather than a hazard ratio.

What the sequencing vendors are buying is not what Moderna shareholders are buying. Intismeran is assembled for each patient from the mutations in that patient's own tumor, which is the link GEN draws between the sponsors' news and the instrument makers ^[4]. Vendor revenue therefore tracks the number of patients treated rather than the size of the benefit each one receives: a modest effect across a broad label sells more sequencing than a large effect in a narrow one. That also moves the sequencing bill from a study budget into the recurring input cost of every dose manufactured.

Oxford Nanopore is the leg of the rally to discount. Its 39% gain came with a first-half revenue increase of 10.5%, to 116.7m pounds ^[8], CEO Francis Van Parys restating a target above 700m pounds by 2030 ^[9], and an intellectual property cross-licence with an undisclosed diagnostics developer ^[10]. The disclosed cash in that licence is $35m ^[6], roughly 22% of the half-year's revenue ^[7], though it lands between the second half of 2026 and 2028. The 2030 target implies about 24.6% compound annual growth from the current half-year run rate ^[8], against the 10.5% just delivered ^[8]. Personalised oncology is one of the few end markets big enough to close a gap of that shape, which is precisely why the share price is a poor instrument for measuring it.

The give-back is the part worth keeping. The $45bn added to Moderna's market value on announcement day implies a pre-announcement equity value near $25.4bn ^[11][2]; by Friday's close about $33bn of that increase remained, with roughly $12bn gone ^[3]. Peak to Friday is a 16.8% decline ^[4], after a 24% single-day drop that GEN attributes to profit-taking and to a broad market fall on expectations of a longer Iran war ^[13]. Of the two upgrades, William Blair's Myles Minter went to Outperform, calling the update a clear positive for Moderna's fundamental business ^[16], while BofA's Alec Stranahan went only as far as Neutral with a $170 twelve-month target ^[17], about 17% above where the shares finished the week ^[9]. The most quoted phrase of the week, "a watershed moment", arrived attached to that Neutral rating ^[17].